Literature DB >> 22972105

Black cohosh (Cimicifuga spp.) for menopausal symptoms.

Matthew J Leach1, Vivienne Moore.   

Abstract

BACKGROUND: Menopause can be a distressing and disruptive time for many women, with many experiencing hot flushes, night sweats, vaginal atrophy and dryness. Postmenopausal women are also at increased risk of osteoporosis. Interventions that decrease the severity and frequency of these menopausal symptoms are likely to improve a woman's well-being and quality of life. Hormone therapy has been shown to be effective in controlling the symptoms of menopause; however, many potentially serious adverse effects have been associated with this treatment. Evidence from experimental studies suggests that black cohosh may be a biologically plausible alternative treatment for menopause; even so, findings from studies investigating the clinical effectiveness of black cohosh have, to date, been inconsistent.
OBJECTIVES: To evaluate the clinical effectiveness and safety of black cohosh (Cimicifuga racemosa or Actaea racemosa) for treating menopausal symptoms in perimenopausal and postmenopausal women. SEARCH
METHODS: Relevant studies were identified through AARP Ageline, AMED, AMI, BioMed Central gateway, CAM on PubMed, CINAHL, CENTRAL, EMBASE, Health Source Nursing/Academic edition, International Pharmaceutical Abstracts, MEDLINE, Natural medicines comprehensive database, PsycINFO, TRIP database, clinical trial registers and the reference lists of included trials; up to March 2012. Content experts and manufacturers of black cohosh extracts were also contacted. SELECTION CRITERIA: All randomised controlled trials comparing orally administered monopreparations of black cohosh to placebo or active medication in perimenopausal and postmenopausal women. DATA COLLECTION AND ANALYSIS: Two review authors independently selected trials, extracted data and completed the 'Risk of bias' assessment. Study authors were contacted for missing information. MAIN
RESULTS: Sixteen randomised controlled trials, recruiting a total of 2027 perimenopausal or postmenopausal women, were identified. All studies used oral monopreparations of black cohosh at a median daily dose of 40 mg, for a mean duration of 23 weeks. Comparator interventions included placebo, hormone therapy, red clover and fluoxetine. Reported outcomes included vasomotor symptoms, vulvovaginal symptoms, menopausal symptom scores and adverse effects. There was no significant difference between black cohosh and placebo in the frequency of hot flushes (mean difference (MD) 0.07 flushes per day; 95% confidence interval (CI) -0.43 to 0.56 flushes per day; P=0.79; 393 women; three trials; moderate heterogeneity: I(2) = 47%) or in menopausal symptom scores (standardised mean difference (SMD) -0.10; 95% CI -0.32 to 0.11; P = 0.34; 357 women; four trials; low heterogeneity: I(2) = 21%). Compared to black cohosh, hormone therapy significantly reduced daily hot flush frequency (three trials; data not pooled) and menopausal symptom scores (SMD 0.32; 95% CI 0.13 to 0.51; P=0.0009; 468 women; five trials; substantial heterogeneity: I(2) = 69%). These findings should be interpreted with caution given the heterogeneity between studies. Comparisons of the effectiveness of black cohosh and other interventions were either inconclusive (because of considerable heterogeneity or an insufficient number of studies) or not statistically significant. Similarly, evidence on the safety of black cohosh was inconclusive, owing to poor reporting. There were insufficient data to pool results for health-related quality of life, sexuality, bone health, vulvovaginal atrophic symptoms and night sweats. No trials reported cost-effectiveness data. The quality of included trials was generally unclear, owing to inadequate reporting. AUTHORS'
CONCLUSIONS: There is currently insufficient evidence to support the use of black cohosh for menopausal symptoms. However, there is adequate justification for conducting further studies in this area. The uncertain quality of identified trials highlights the need for improved reporting of study methods, particularly with regards to allocation concealment and the handling of incomplete outcome data. The effect of black cohosh on other important outcomes, such as health-related quality of life, sexuality, bone health, night sweats and cost-effectiveness also warrants further investigation.

Entities:  

Mesh:

Year:  2012        PMID: 22972105      PMCID: PMC6599854          DOI: 10.1002/14651858.CD007244.pub2

Source DB:  PubMed          Journal:  Cochrane Database Syst Rev        ISSN: 1361-6137


  41 in total

1.  A Black Cohosh Extract Causes Hematologic and Biochemical Changes Consistent with a Functional Cobalamin Deficiency in Female B6C3F1/N Mice.

Authors:  Michelle C Cora; William Gwinn; Ralph Wilson; Debra King; Suramya Waidyanatha; Grace E Kissling; Sukhdev S Brar; Dorian Olivera; Chad Blystone; Greg Travlos
Journal:  Toxicol Pathol       Date:  2017-06-15       Impact factor: 1.902

2.  Mechanistic Evaluation of Black Cohosh Extract-Induced Genotoxicity in Human Cells.

Authors:  Ji-Eun Seo; Xiaoqing Guo; Dayton M Petibone; Sharon D Shelton; Ying Chen; Xilin Li; Volodymyr Tryndyak; Stephanie L Smith-Roe; Kristine L Witt; Nan Mei; Mugimane G Manjanatha
Journal:  Toxicol Sci       Date:  2021-07-16       Impact factor: 4.849

Review 3.  Efficacy and Safety of Needle Acupuncture for Treating Gynecologic and Obstetric Disorders: An Overview.

Authors:  Anna Selva Olid; María José Martínez Zapata; Ivan Solà; Zoran Stojanovic; Sonia Maria Uriona Tuma; Xavier Bonfill Cosp
Journal:  Med Acupunct       Date:  2013-12-01

4.  Motivations for Botanical Use by Socioeconomically Diverse, Urban Adults: Does Evidence Support Motivation?

Authors:  Grace F Duffy; Emily Stave Shupe; Marie Fanelli Kuczmarski; Alan B Zonderman; Michele K Evans
Journal:  J Altern Complement Med       Date:  2017-02-16       Impact factor: 2.579

5.  Principles of pharmacological research of nutraceuticals.

Authors:  Ruth Andrew; Angelo A Izzo
Journal:  Br J Pharmacol       Date:  2017-06       Impact factor: 8.739

6.  [Herbal medicines: when to use or not to use?].

Authors:  K Mörike; C H Gleiter
Journal:  Internist (Berl)       Date:  2014-11       Impact factor: 0.743

7.  Clinical guidelines for gynecologic care after hematopoietic SCT. Report from the international consensus project on clinical practice in chronic GVHD.

Authors:  B Frey Tirri; P Häusermann; H Bertz; H Greinix; A Lawitschka; C-P Schwarze; D Wolff; J P Halter; D Dörfler; R Moffat
Journal:  Bone Marrow Transplant       Date:  2014-10-27       Impact factor: 5.483

8.  Survivorship, Version 2.2017, NCCN Clinical Practice Guidelines in Oncology.

Authors:  Crystal S Denlinger; Tara Sanft; K Scott Baker; Shrujal Baxi; Gregory Broderick; Wendy Demark-Wahnefried; Debra L Friedman; Mindy Goldman; Melissa Hudson; Nazanin Khakpour; Allison King; Divya Koura; Elizabeth Kvale; Robin M Lally; Terry S Langbaum; Michelle Melisko; Jose G Montoya; Kathi Mooney; Javid J Moslehi; Tracey O'Connor; Linda Overholser; Electra D Paskett; Jeffrey Peppercorn; M Alma Rodriguez; Kathryn J Ruddy; Paula Silverman; Sophia Smith; Karen L Syrjala; Amye Tevaarwerk; Susan G Urba; Mark T Wakabayashi; Phyllis Zee; Deborah A Freedman-Cass; Nicole R McMillian
Journal:  J Natl Compr Canc Netw       Date:  2017-09       Impact factor: 11.908

Review 9.  A clinical guide to the management of genitourinary symptoms in breast cancer survivors on endocrine therapy.

Authors:  Mariana S Sousa; Michelle Peate; Sherin Jarvis; Martha Hickey; Michael Friedlander
Journal:  Ther Adv Med Oncol       Date:  2017-01-31       Impact factor: 8.168

Review 10.  Chinese herbal medicine for menopausal symptoms.

Authors:  Xiaoshu Zhu; Yuklan Liew; Zhao Lan Liu
Journal:  Cochrane Database Syst Rev       Date:  2016-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.